TECHNOLOGIES    
 
 
Al Rehemtulla, Ph.D.
   Chairman, Chief Executive Officer and Founder
  
Dr. Alnawaz Rehemtulla is a founder and the CEO of Molecular Therapeutics, Inc. He received his doctoral degree from the University of Calgary Medical School and post graduate training at the Scripps Research Institute in San Diego. He then joined Genetics Institute in Boston, MA where he was responsible for the development of recombinant Factor IX as a therapeutic agent for Hemophilia B. This product is currently marketed with annual sales of $500M. He is also a Professor of Radiation Oncology at the University of Michigan Medical School and a founding Editor of Neoplasia, an international cancer research journal. 
 
   
Brian D. Ross, Ph.D.
   President and Founder
 
Dr. Brian D. Ross is a founder and President of Molecular Therapeutics, Inc. He received his doctoral degree from the University of California at Davis. He received a postgraduate Fellowship from the American Brain Tumor and conducted research at the University of Minnesota, Center for Magnetic Resonance Research in cancer biology and imaging. Dr. Ross is also a Professor of Radiology and Biological Chemistry at the University of Michigan where he also serves as a founder and Co-Director of the Center for Molecular Imaging.
 
   
Prasad Sunkara , Ph.D.
   Scientific Consultant and Founder
 
Dr. Sunkara has more than 30 years of research and development management experience in cancer, cardiovascular and CNS disease indications at a major pharma and a number of biotech companies. He was the Executive Vice President of Research and Development of Cytovia, Inc, before its merger with Maxim Pharmaceuticals, Inc. He was the Vice President of Drug Development for Cytokine Networks, Inc. and was instrumental in clinical development of small molecule inhibitor of TNF for cancer, psoriasis and Inflammatory bowel disease indications that helped in the merger of the company with Cytokine Pharmasciences, Inc. Before that, he was founding Director of Product Development at Neurocrine Biosciences, Inc. in San Diego. He was the Head of Tumor Biology responsible for research and preclinical development of cancer and antiviral therapeutics at Marion Merrell Dow Research Institute in Cincinnati.
 
   
W.R. (Dick) Leopold, Ph.D
   Scientific Consultant and CEO of Molecular Imaging Research, Inc.
 
Dr. Leopold has more than 28 years of research and management experience in the field of cancer research and drug development. Dr. Leopold has extensive professional experience in cancer drug discovery and evaluation, target validation, clinical development of anticancer agents, contract research, toxicology, and engineering. His personal research interests have focused on various technologies for in vivo evaluation of anticancer potential and the in vivo assessment of drug function at the molecular level. Prior to joining MIR, Dr. Leopold was Executive Director of Cancer Pharmacology and Therapeutic Area Site Leader for Oncology at Pfizer's Ann Arbor Laboratories. He was a co-founder of the Cancer Drug Discovery Program at Parke-Davis in 1982, assuming leadership of the program in 1989. During his tenure at Parke Davis/Pfizer, more than 18 novel agents spanning at least 10 mechanistic classes were discovered and developed to clinical trial. Upon completion of his Ph.D., Dr. Leopold joined the Chemotherapy Division of Southern Research Institute as a Research Oncologist where he also worked in the Toxicology Division as a Research Toxicologist. Dr. Leopold received his Ph.D. in Oncology from the McArdle Institute for Cancer Research at theUniversity of Wisconsin. He also holds an M.S. in Biochemistry and a B.S. in Chemical Engineering, both from the University of Illinois.
 
   
Judi Weissinger, Ph.D
   Regulatory Consultant
 
Dr. Weissinger is President and CEO of Weissinger Solutions, Inc., a consulting and contract service group providing strategic guidance for global regulatory challenges applicable to pharmaceutical, medical device, and biological products. Dr. Weissinger has been in the regulatory field for over 30 years, with about ten years each in academia, at FDA, and in industry. While in industry, in addition to consulting, Dr. Weissinger was Vice President of Regulatory Affairs and of Quality Assurance at Applied Immune Sciences and PRP Gencell, and a Director of Regulatory Affairs and Preclinical and Clinical Compliance at Glaxo Research Institute. While at FDA, Dr. Weissinger was pivotally involved in ICH while serving as the head of Pharmacology/Toxicology at CDER and at CBER to develop policy that impacted on national and international safety standards. At FDA she was initially a reviewer of human food safety at CVM, and detailed as acting Deputy Director of OST, CDRH.
 
   
Sudhir Borgonha , MD, MBA
   Medical Consultant
 
Dr. Borgonha has vast experiences in the conduct of clinical research in India and the United States as well as the global management of various clinical research projects. He is a graduate of St. John’s Medical College, Bangalore, India and the Sloan School of Management, MIT, Cambridge, MA. Most recently, he was the Chief Executive Officer of Triesta Sciences, a clinical genomics company focused on RNA and DNA fingerprints in Oncology. A successful entrepreneur, he has been instrumental in starting two biotechnology companies, Angstrom Medica and Triesta Sciences. While at the Harvard-MIT Clinical Research Center, Cambridge, MA, he led the clinical research team focused on metabolomics in various disease conditions, including HIV, pediatrics and metabolic processing in healthy adults.
 
   
William R. Grove, MS
   Clinical Consultant
 
Mr. Grove has over 30 years of clinical trial experience in the field of oncology. His most recent experience was as Director, Clinical Oncology for Parke-Davis/Pfizer, where he spent 18 years directing and managing Phase I, II, and III clinical trials of anticancer agents. Prior to working in the pharmaceutical industry, Mr. Grove was the Director of the Clinical Research Pharmacy Service at the University of Maryland Cancer Center, Baltimore. Mr. Grove received his Bachelor of Science in Pharmacy from Temple University School of Pharmacy and received his Masters Degree in Pharmacy at the University of Maryland School of Pharmacy.
 
   
Gregory S. Miller, CPA
   Controller
 
Mr. Miller has a broad financial background with significant experience in business operations and development, financial accounting, financial analysis and administration established over his 19 year career. Mr. Miller has spent most of his career in private industry in fields such as telecommunications, retail, Internet and healthcare. He has held a variety of financial positions in companies such as Domino's Pizza, Border's Books & Music and Cabletron. Mr. Miller received his Bachelor of Business Administration degree from Western Michigan University.
 
   
 
MAP